HORIZONS AMI Focus Center

Presentations from SCAI-ACC 2008

Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction: The HORIZONS AMI Trial by Dr. George D. Dangas

Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial by Dr. Bernhard Witzenbichler
 
Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The Horizons AMI Trial by Dr. L. Grinfield
 
Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients with Acute MI Undergoing Primary Angioplasty: The HORIZONS AMI Trial by Dr. Roxana Mehran
 
Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial by Dr. Dariusz Dudek
 
Major Adverse Events in STEMI Patients Treated with Primary Angioplasty Occur More Frequently at U.S. Compared with Non U.S. Sites: Analysis from the HORIZONS AMI Trial by Dr. Bruce R. Brodie
 
Safety and effectiveness of bivalirudin compared to either abciximab or eptifibatide in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial by Dr. Giulio Guagliumi

Presentations from TCT 2007

HORIZONS AMI 30 Day Results Presented by Dr. Gregg Stone at TCT 2007

ACUITY PCI: A Prospective Trial of Patients with ACS Undergoing PCI after Randomization to Heparin plus GP IIb/IIIa Inhibitors vs. Bivalirudin With or Without GP IIb/IIIa Inhibitors Dr. Harvey White on behalf of the ACUITY investigators

Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial  Roxana Mehran, on behalf of the ACUITY investigators

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation ACS Managed with an Invasive Strategy: Results from the Randomized ACUITY Trial  Harvey D. White on behalf of the ACUITY investigators

Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial  Alexandra J. Lansky on behalf of the ACUITY Investigators

Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl for the ACUITY Investigators

Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervetnion: The ACUITY Trial Steven V. Manoukian

Impact of Transfusion on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven V. Manoukian

Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven V. Manoukian

Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights from the ACUITY Trial Steven V. Manoukian

Is It Safe to Switch Antithrombins At the Time of PCI: A Review of Data by C. Michael Gibson, M.S., M.D.

Watch the video by clicking here

Bivalirudin: Using Movies not Words to Show the Benefits: A series of downloadable Powerpoint slide videos presented by CM Gibson.  What does binding to clot bound thrombin look like anyway?

What does it look like to be a "Direct" thrombin inhibitor, and why is that important?

What does it look like to inhibit "Clot bound thrombin", and why is it important?

What does it look like when heparin "gets distracted" and binds to heparin binding proteins while bivalirudin "stays focused" and binds to thrombin only?

Because heparin is non specific and binds to platelet factor 4, it triggers an antibody reaction that in turn is associated with HIT or heparin induced thrombocytopenia

What does it look like when heparin activates platelets and bivalirudin does not?

Why is Bivalirudin associated with less bleeding? See how it becomes inactivated when it falls off thrombin, unlike heparin which remains active

ACUITY Overall Results

ACUITY Overall Results Presented by Dr. G Stone

ACUITY Timing Results Presented by Dr. G Stone

ACUITY PCI Results Presented by Dr. G Stone, TCT 2006

ACUITY Substudy Results

ACUITY Transfusion Results S. Manoukian, TCT 2006

ACUITY Diabetic Results F Feit, AHA 2006

ACUITY Elderly Results K Alexander, TCT 2006